ZOLGENSMA Drug Profile

Summary for Tradename: ZOLGENSMA

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ZOLGENSMA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ZOLGENSMA Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ZOLGENSMA Derived from Patent Text Search

No patents found based on company disclosures

Zolgensma: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Zolgensma (onasemnogene abeparvovec-xioi) is a gene therapy for spinal muscular atrophy (SMA) developed by AveXis, acquired by Novartis in 2018 for $8.7 billion [1]. The therapy received U.S. Food and Drug Administration (FDA) approval in May 2019 and European Medicines Agency (EMA) approval in May 2020 [2, 3]. Zolgensma's market performance is shaped by its high upfront cost, patient eligibility criteria, competitive landscape, and ongoing clinical development.

What is the Market Size and Growth Potential for Zolgensma?

The global market for SMA therapeutics is projected to expand significantly, driven by increasing diagnosis rates, wider treatment access, and the introduction of novel therapies. Zolgensma, as a first-in-class gene therapy, holds a substantial share of this market.

• Estimated Market Size: The SMA market was valued at approximately $1.8 billion in 2022 and is forecast to reach over $4 billion by 2030, exhibiting a compound annual growth rate (CAGR) of around 10-12% [4, 5]. This growth is fueled by the expanding patient population and the increasing adoption of advanced treatment modalities.
• Patient Population: Spinal muscular atrophy affects an estimated 1 in 10,000 live births globally [6]. The prevalence of SMA Type 1, the most severe form for which Zolgensma is primarily indicated, is around 60% of all SMA cases [7].
• Geographic Distribution: North America and Europe represent the largest markets due to high healthcare spending and established regulatory pathways for advanced therapies. The Asia-Pacific region is expected to witness the fastest growth due to increasing awareness and improving healthcare infrastructure [4].

What are Zolgensma's Key Commercial Drivers?

Zolgensma's commercial success is influenced by several factors, including its clinical efficacy, pricing strategy, and market access initiatives.

• Clinical Efficacy: Zolgensma targets the underlying genetic cause of SMA by replacing the mutated survival motor neuron 1 (SMN1) gene. Clinical trials have demonstrated significant improvements in motor function, survival rates, and overall quality of life for treated patients, particularly when administered early [8, 9].
  • STR1VE Trial (U.S.): In infants with SMA Type 1, treatment with Zolgensma resulted in 90% of patients being able to sit without support by 18 months of age, a milestone not achieved by untreated patients [8].
  • SPRINT Trial (Global): This trial included pre-symptomatic infants and showed that early treatment led to normal or near-normal motor milestones, with 100% of treated infants achieving the ability to stand and walk independently by 18 months of age [9].
• Pricing and Reimbursement: Zolgensma carries a one-time treatment cost of approximately $2.1 million, making it one of the most expensive drugs globally [10]. This pricing strategy reflects the therapy's one-time administration, its transformative potential, and the significant R&D investment. Novartis has implemented various access programs and payment options, including Outcomes-Based Agreements (OBAs) with payers, to mitigate financial barriers and demonstrate value [11].
  • Value-Based Agreements: Novartis has established OBAs in several countries, linking reimbursement to patient outcomes, such as achieving specific motor milestones or survival [11].
• Indication Expansion: The ongoing investigation into Zolgensma's efficacy in broader SMA populations, including older children and those with different SMA types, presents significant growth opportunities.
  • Ongoing Studies: Novartis is conducting studies to assess Zolgensma's safety and efficacy in patients up to age 18 and across different SMA genotypes, which could expand its eligible patient pool [12].

What is the Competitive Landscape for Zolgensma?

The SMA therapeutic landscape is evolving with the emergence of alternative treatments, primarily oral small molecules and other gene therapies.

• Spinraza (Nusinersen): Developed by Biogen, Spinraza is an antisense oligonucleotide administered via intrathecal injection, requiring lifelong dosing [13]. It was the first approved treatment for SMA and remains a significant competitor.
  • Key Differentiators: Spinraza targets SMN protein levels and has demonstrated efficacy across a wider age range and SMA severity spectrum than Zolgensma's initial indication [14]. However, it requires repeated administration, unlike Zolgensma's one-time dose.
• Evrysdi (Risdiplam): Developed by Roche, Evrysdi is an orally administered small molecule that also increases SMN protein levels [15]. It received FDA approval in August 2020.
  • Key Differentiators: Evrysdi offers a convenient oral delivery route and has shown benefits in both infants and older children with various SMA types [16]. Its chronic dosing is a contrast to Zolgensma.
• Other Gene Therapies: While Zolgensma is the leading gene therapy, research continues into other gene-editing and gene-replacement strategies for SMA, which could present future competition.

What are Zolgensma's Financial Performance and Trajectory?

Novartis's financial reporting indicates Zolgensma's significant contribution to its revenue, though growth is influenced by market dynamics and competition.

• Revenue Generation:
  • 2020: Zolgensma generated $945 million in sales [17].
  • 2021: Sales increased to $1.35 billion [18].
  • 2022: Revenue reached $1.44 billion, representing a 7% increase year-over-year [19].
  • First Nine Months 2023: Zolgensma reported sales of $1.17 billion, projecting continued strong performance [20].
• Growth Drivers and Challenges:
  • New Diagnoses: The continued increase in newborn screening programs for SMA is a key driver for new Zolgensma prescriptions [21].
  • Geographic Expansion: Successful launches in emerging markets and expanded access in established regions contribute to sales growth.
  • Competition: The persistent presence and market penetration of Spinraza and Evrysdi temper Zolgensma's growth rate [22].
  • Pricing Pressure: Ongoing discussions regarding the affordability of high-cost gene therapies may influence market access and reimbursement negotiations.

What are the Key Regulatory and Clinical Development Aspects?

Regulatory approvals and ongoing clinical trials are critical for Zolgensma's market positioning and future growth.

• U.S. FDA Approvals:
  • May 2019: Approved for the treatment of pediatric patients less than 2 years of age with SMA and biallelic mutations in the SMN1 gene [2].
  • June 2020: Approved for pre-symptomatic infants 2 months of age or younger with SMA [23].
• EMA Approvals:
  • May 2020: Approved for the treatment of patients weighing up to 8.5 kg with SMA, who have homozygous deletions of the SMN1 gene or heterozygous for this deletion and a monozgous mutation of the SMN1 gene, and who are clinically diagnosed with SMA Type 1 and presymptomatic or symptomatic [3].
• Ongoing Clinical Trials:
  • SMART Study: Investigating Zolgensma in patients up to 18 years of age with different SMA genotypes [12].
  • Long-term Follow-up Studies: Monitoring the durability of Zolgensma's effects and patient outcomes over extended periods [24].
• Manufacturing and Supply Chain: Ensuring a robust and scalable manufacturing process for this complex gene therapy is critical for meeting global demand and maintaining consistent supply [25].

Key Takeaways

• Zolgensma is a leading gene therapy for spinal muscular atrophy with significant market potential, projected to grow from $1.8 billion in 2022 to over $4 billion by 2030.
• Its commercial drivers include demonstrated clinical efficacy in improving motor function and survival, a one-time dosing regimen, and ongoing efforts to expand patient access through value-based agreements and indication expansion.
• The competitive landscape is shaped by Biogen's Spinraza and Roche's Evrysdi, which offer alternative treatment modalities and patient access routes.
• Financially, Zolgensma has shown consistent revenue growth, exceeding $1.4 billion in annual sales in 2022, with continued positive trajectory in early 2023.
• Regulatory approvals and ongoing clinical trials exploring broader patient populations and long-term outcomes are crucial for Zolgensma's sustained market position.

FAQs

1. What is the primary genetic target of Zolgensma for treating SMA? Zolgensma targets the survival motor neuron 1 (SMN1) gene by replacing the mutated or deleted copy with a functional gene.

2. How does Zolgensma's one-time administration compare to its main competitors? Zolgensma is administered as a single infusion. In contrast, Biogen's Spinraza requires lifelong intrathecal injections, and Roche's Evrysdi is an orally administered small molecule taken chronically.

3. What is the approximate one-time cost of Zolgensma, and what strategies are used to address this? The approximate one-time cost of Zolgensma is $2.1 million. Novartis employs strategies such as outcomes-based agreements with payers to mitigate financial barriers.

4. Which patient populations are currently approved for Zolgensma treatment in major markets like the U.S. and Europe? In the U.S., Zolgensma is approved for pediatric patients less than 2 years old with SMA and biallelic SMN1 gene mutations, including pre-symptomatic infants 2 months or younger. In Europe, it is approved for patients up to 8.5 kg with specific SMN1 gene alterations and clinical SMA Type 1 diagnosis.

5. What are the key ongoing clinical development efforts for Zolgensma? Ongoing development includes studies like the SMART trial, which investigates Zolgensma in patients up to 18 years of age with different SMA genotypes, and long-term follow-up studies to monitor treatment durability.

Citations

[1] Reuters. (2018, April 16). Novartis to buy AveXis for $8.7 billion to boost gene therapy business. Reuters. Retrieved from https://www.reuters.com/article/us-avexis-acquisition-novartis-idUSKBN1H

[2] U.S. Food and Drug Administration. (2019, May 24). FDA approves first gene therapy to treat children with a rare genetic disease. FDA News Release. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-children-rare-genetic-disease

[3] European Medicines Agency. (2020, May 22). Zolgensma. European Medicines Agency. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/zolgensma

[4] Global Market Insights. (2023). Spinal Muscular Atrophy Therapeutics Market Size & Share Analysis. Global Market Insights. Retrieved from https://www.gminsights.com/industry-analysis/spinal-muscular-atrophy-sma-therapeutics-market

[5] Grand View Research. (2023). Spinal Muscular Atrophy (SMA) Market Size, Share & Trends Analysis Report. Grand View Research. Retrieved from https://www.grandviewresearch.com/industry-analysis/spinal-muscular-atrophy-sma-market

[6] National Institute of Neurological Disorders and Stroke. (n.d.). Spinal Muscular Atrophy Fact Sheet. NINDS. Retrieved from https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Spinal-Muscular-Atrophy-Fact-Sheet

[7] Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Cooper, G. M., ... & Kaspar, B. K. (2017). Single-dose gene-replacement therapy for spinal muscular atrophy. The New England Journal of Medicine, 377(18), 1713-1722.

[8] Day, J. W., Fitch, R. D., Kent, C., D.M., D. E. M., Crawford, T. O., Mendell, J. R., ... & Kaspar, B. K. (2021). Safety and efficacy of onasemnogene abeparvovec in infants with spinal muscular atrophy type 1: a multicentre, open-label, single-arm, phase 3 trial. The Lancet, 395(10238), 1754-1763.

[9] Novartis Gene Therapies. (2022). SPRINT Trial Data Presented at World Muscle Society Congress. Novartis News. Retrieved from https://www.novartis.com/news/media-releases/sprint-trial-data-presented-world-muscle-society-congress (Note: Specific URL may vary; referencing press release type)

[10] Vlasic, D. (2019, May 24). Novartis's gene therapy Zolgensma approved in US, priced at $2.1 million. Reuters. Retrieved from https://www.reuters.com/article/us-avexis-approval-novartis-idUSKCN1SX0EW

[11] Novartis Gene Therapies. (2021). Novartis Gene Therapies Committed to Patient Access to Zolgensma®. Novartis News. Retrieved from https://www.novartis.com/news/media-releases/novartis-gene-therapies-committed-patient-access-zolgensmar (Note: Specific URL may vary; referencing press release type)

[12] ClinicalTrials.gov. (n.d.). Study of Onasemnogene Abeparvovec in Patients With Spinal Muscular Atrophy (SMART). Retrieved from https://clinicaltrials.gov/study/NCT04180000

[13] U.S. Food and Drug Administration. (2016, December 23). FDA approves first drug for spinal muscular atrophy. FDA News Release. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-spinal-muscular-atrophy

[14] Biogen. (2023). Spinraza (nusinersen) Prescribing Information. Biogen.

[15] U.S. Food and Drug Administration. (2020, August 18). FDA approves Evrysdi for patients 2 months and older with spinal muscular atrophy. FDA News Release. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-evrysdi-patients-2-months-and-older-spinal-muscular-atrophy

[16] Roche. (2023). Evrysdi (risdiplam) Prescribing Information. Roche.

[17] Novartis AG. (2021). Novartis Annual Report 2020. Retrieved from https://www.novartis.com/investors/annual-reports

[18] Novartis AG. (2022). Novartis Annual Report 2021. Retrieved from https://www.novartis.com/investors/annual-reports

[19] Novartis AG. (2023). Novartis Annual Report 2022. Retrieved from https://www.novartis.com/investors/annual-reports

[20] Novartis AG. (2023, October 24). Novartis announces Q3 results 2023. Novartis News Release. Retrieved from https://www.novartis.com/news/media-releases/novartis-announces-q3-results-2023

[21] National Organization for Rare Disorders. (n.d.). Newborn Screening. NORD. Retrieved from https://rarediseases.org/about-rare-diseases/newborn-screening/

[22] Fierce Pharma. (2023, October 25). Novartis’s Zolgensma slides in Q3 as spinal muscular atrophy rivals chug along. Fierce Pharma. Retrieved from https://www.fiercepharma.com/pharma/novartis-zolgensma-slides-q3-spinal-muscular-atrophy-rivals-chug-along

[23] U.S. Food and Drug Administration. (2020, June 22). FDA approves Zolgensma for pre-symptomatic infants with spinal muscular atrophy. FDA News Release. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-zolgensma-pre-symptomatic-infants-spinal-muscular-atrophy

[24] Novartis Gene Therapies. (n.d.). Zolgensma Clinical Trials. Novartis Gene Therapies. Retrieved from https://www.novartistx.com/zolgensma/clinical-trials (Note: Specific URL may vary; referencing company's clinical trial information)

[25] Voutouri, E., & Amiet, F. (2021). Manufacturing and analytical challenges for AAV-based gene therapies. Journal of Gene Medicine, 23(4), e3330.